目的 探讨丹杞颗粒联合地舒单抗注射液治疗骨质疏松症的临床疗效。方法 将黄山首康医院在2022年7月—2024年5月收治的92例骨质疏松症患者作为研究对象，按随机数字表法将患者分为对照组和治疗组，每组46例。对照组单次皮下注射地舒单抗注射液，每6个月1次。治疗组在对照组基础上温开水冲服丹杞颗粒，1袋/次，2次/d，3个月为1个疗程，持续治疗2个疗程。两组在治疗6个月后统计治疗效果。比较两组的治疗效果、全身骨痛程度、骨密度、血清指标。结果 治疗组的总有效率为93.48%，对照组的总有效率为78.26%，组间比较差异有统计学意义（P＜0.05）。治疗后，两组的VAS评分均低于治疗前（P＜0.05）；治疗组的VAS评分低于对照组（P＜0.05）。治疗后，两组的股骨颈、腰椎L₁～L₄、Wards三角区骨密度高于治疗前（P＜0.05）；治疗组的股骨颈、腰椎L₁～L₄、Wards三角区骨密度高于对照组（P＜0.05）。治疗后，两组的血清N端中段骨钙素（N-MID）、β-Ⅰ型胶原羧基端肽（β-CTX）水平低于治疗前，血清I型前胶原羧基端肽（PICP）水平高于治疗前（P＜0.05）；治疗组的血清N-MID、β-CTX水平低于对照组，血清PICP水平高于对照组（P＜0.05）。治疗后，两组的血清白细胞介素-17（IL-17）、肿瘤坏死因子-α（TNF-α）水平低于治疗前（P＜0.05）；治疗组的血清IL-17、TNF-α水平低于对照组（P＜0.05）。结论 丹杞颗粒联合地舒单抗注射液可提高骨质疏松症的临床疗效，减轻全身骨痛程度，提高骨密度，调节骨代谢指标，减轻炎症反应。

Objective To explore the clinical efficacy of Danqi Granules combined with Denosumab Injection in treatment of osteoporosis. Methods 92 Patients with osteoporosis in Huangshan Shoukang Hospital from July 2022 to May 2024 were selected, and were divided into control group and treatment group by random number table method, with 46 cases in each group. Patients in the control group were sc administered with Denosumab Injection every 6 months. On the basis of the control group, patients in the treatment group were po administered with Danqi Granules with warm water, 1 bag/time, twice daily, for 3 months as one course of treatment, and continued for 2 courses of treatment. After 6 months of treatment, the treatment effects of the two groups were statistically analyzed. Treatment efficacy, degree of systemic bone pain, bone density, and serum indicators between two groups were compared. Results The total effective rate of the treatment group was 93.48%, while the total effective rate of the control group was 78.26%,and the difference between two groups was statistically significant (P < 0.05). After treatment, the VAS scores of both groups were lower than those before treatment (P < 0.05), and the VAS scores of the treatment group were lower than those of the control group (P < 0.05). After treatment, the bone density of the femoral neck, lumbar vertebrae L₁— L₄, and Ward's triangle in both groups was higher than those before treatment (P < 0.05), and the bone densities of the femoral neck, lumbar vertebrae L₁— L₄, and Wards triangle in the treatment group were higher than those in the control group (P < 0.05). After treatment, the levels of serum N-terminal mid segment osteocalcin (N-MID) and β-type I collagen carboxy terminal peptide (β-CTX) in both groups were lower than those before treatment, and the level of serum type I procollagen carboxy terminal peptide (PICP) was higher than those before treatment (P < 0.05). The serum levels of N-MID and β-CTX in the treatment group were lower than those in the control group, but the serum PICP level was higher than that in the control group (P < 0.05). After treatment, the levels of serum interleukin-17 (IL-17) and tumor necrosis factor-α (TNF-α) in both groups were lower than those before treatment (P < 0.05), and the serum levels of IL-17 and TNF-α in the treatment group were lower than those in the control group (P < 0.05). Conclusion Danqi Granules combined with Denosumab Injection can improve the clinical efficacy of osteoporosis, reduce systemic bone pain, increase bone density, regulate bone metabolism indicators, and alleviate inflammatory reactions.

R982